Long COVID and Peripheral Neuropathy: Clinical Phenotypes, Pathobiology, Diagnosis, and Treatment

John Murphy, CEO, The Covid-19 Long Haul Foundation

A Narrative Review

Abstract

Importance: Peripheral nervous system dysfunction is increasingly recognized among the neurological manifestations of Long COVID. Small-fiber neuropathy (SFN), autonomic dysfunction, large-fiber neuropathy, and immune-mediated demyelinating neuropathies have all been described. SFN is particularly challenging because conventional electrodiagnostic studies may be normal despite substantial sensory and autonomic disability.

Observations: Patients with Long COVID may develop burning pain, paresthesia’s, numbness, dysesthesia, altered temperature perception, allodynia, autonomic dysfunction, orthostatic intolerance, abnormal sweating, gastrointestinal or genitourinary dysfunction, and impaired gait or balance. Several observational cohorts have demonstrated reduced intraepidermal nerve-fiber density on skin biopsy in selected patients with post–COVID-19 neuropathic symptoms. Proposed mechanisms include immune dysregulation, autoimmunity, molecular mimicry, endothelial and neurovascular dysfunction, persistent viral antigen, complement activation, microvascular injury, and altered neuroimmune signaling. Genetic susceptibility is plausible, but no genomic marker currently establishes susceptibility to Long COVID-associated neuropathy. Diagnosis requires neurological phenotyping and exclusion of common causes of neuropathy. Nerve-conduction studies and electromyography are useful for large-fiber and demyelinating disease but may be normal in SFN. Skin biopsy, quantitative sensory testing, and autonomic studies can provide complementary objective evidence. Treatment is presently directed principally toward identifiable causes, neuropathic symptoms, autonomic dysfunction, and preservation of function. Intravenous immunoglobulin and other immunomodulatory approaches remain investigational.

Conclusions and Relevance: Long COVID-associated neuropathy should be regarded as a heterogeneous group of peripheral neurological phenotypes rather than a single disorder. SFN is an objectively demonstrable phenotype in a subset of patients and warrants consideration when neuropathic symptoms persist despite normal routine electrodiagnostic studies. Prospective studies integrating neurological examination, skin pathology, autonomic physiology, immunology, genomics, and longitudinal outcomes are needed to determine causality, identify biologically distinct subgroups, and establish disease-modifying treatment.

Introduction

The neurological consequences of SARS-CoV-2 infection extend considerably beyond the acute phase of respiratory disease. Persistent cognitive dysfunction, headache, sleep disturbance, anosmia, dysautonomia, postexertional malaise, and peripheral sensory symptoms are now recognized components of the heterogeneous condition generally referred to as Long COVID or post–COVID-19 condition.1-4

Peripheral neuropathy presents a particularly important diagnostic problem. Patients may describe burning feet, electric-shock sensations, numbness, painful sensitivity, unexplained temperature abnormalities, deep pruritus, impaired sweating, orthostatic intolerance, gastrointestinal dysmotility, urinary dysfunction, or sexual dysfunction. Yet conventional magnetic resonance imaging may be normal, and nerve-conduction studies may show no abnormality.

This apparent contradiction is readily explained by the anatomy of the peripheral nervous system. Standard nerve-conduction studies primarily evaluate large myelinated fibers. Small unmyelinated C fibers and thinly myelinated A-delta fibers, which transmit pain and temperature and participate extensively in autonomic regulation, are poorly assessed by routine electrodiagnostic testing.

Small-fiber neuropathy therefore provides a potentially important anatomical explanation for a subset of patients whose neurological symptoms otherwise remain difficult to objectify.

The emergence of skin biopsy and quantitative sensory testing has made it possible to investigate this phenotype more rigorously. Several studies have reported reduced intraepidermal nerve-fiber density in patients with persistent neuropathic symptoms after SARS-CoV-2 infection.5-8 These observations do not establish that SARS-CoV-2 directly injured peripheral nerves in every affected patient, but they provide evidence that at least some post-COVID neuropathic syndromes have an objective peripheral neurological substrate.

The central clinical challenge is therefore to distinguish neuropathy occurring after COVID-19 from neuropathy caused by mechanisms attributable to SARS-CoV-2 or the postinfectious state.

That distinction requires more than temporal association.

Clinical Phenotypes

Peripheral neurological manifestations following SARS-CoV-2 infection encompass several distinct phenotypes.

Small-Fiber Neuropathy

SFN affects small sensory and autonomic axons. The principal sensory manifestations are burning, prickling, stabbing, electric, or aching pain; altered temperature perception; paresthesias; and allodynia.

The distribution may be length-dependent, beginning in the toes and feet, or non–length-dependent, involving the trunk, face, upper extremities, or proximal regions. A non–length-dependent distribution may suggest an inflammatory or immune-mediated process rather than the conventional metabolic pattern of distal symmetric polyneuropathy.

Objective examination may reveal reduced pinprick or temperature sensation despite preserved vibration and proprioception. Deep tendon reflexes are usually preserved in isolated SFN.

Autonomic Small-Fiber Dysfunction

The same small fibers that mediate pain and temperature also participate in autonomic regulation.

Patients may therefore develop orthostatic intolerance, tachycardia, abnormal sweating, heat or cold intolerance, gastrointestinal dysmotility, bladder dysfunction, and sexual dysfunction.

The coexistence of neuropathic pain and orthostatic intolerance is particularly suggestive of a small-fiber/autonomic phenotype.

Large-Fiber Neuropathy

Large-fiber involvement produces a different clinical picture.

Loss of vibration or proprioception, sensory ataxia, impaired reflexes, distal weakness, and gait instability should prompt evaluation for large-fiber neuropathy.

Unlike isolated SFN, large-fiber neuropathy is generally detectable by nerve-conduction studies.

Immune-Mediated Demyelinating Neuropathy

Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy are distinct from the more indolent SFN phenotype.

Rapidly progressive weakness, areflexia, respiratory involvement, cranial neuropathies, or rapidly evolving autonomic dysfunction should trigger urgent evaluation for Guillain-Barré syndrome.

Progression over more than 8 weeks with objective demyelination raises consideration of CIDP.

These diagnoses should not be subsumed under the nonspecific label of Long COVID neuropathy because they have different prognoses and established disease-specific treatments.

Etiology and Pathobiology

No single mechanism adequately explains the peripheral neurological manifestations of Long COVID.

The most plausible model is one of biological convergence in which infection initiates different downstream processes in genetically and physiologically susceptible individuals.

Immune Dysregulation

Persistent immune abnormalities have been demonstrated in Long COVID, including alterations in T-cell populations, inflammatory signaling, and adaptive immune responses.9

Such findings are biologically compatible with postinfectious peripheral nerve dysfunction.

Peripheral nerves are not immunologically isolated structures. Axons, Schwann cells, endothelial cells, macrophages, and resident immune cells participate in a highly regulated microenvironment. Disturbance of this environment can produce axonal dysfunction, impaired nerve regeneration, altered nociceptor activity, or inflammatory injury.

The principal unanswered question is whether the immune abnormalities observed in Long COVID are the direct cause of neuropathy, a consequence of tissue injury, or an epiphenomenon accompanying another pathological process.

Autoimmunity and Molecular Mimicry

The possibility of autoimmunity is particularly attractive because several peripheral neuropathies are known to be antibody mediated.

Anti-ganglioside antibodies, for example, are associated with several immune-mediated neuropathies. A recent large observational analysis reported anti-ganglioside antibodies in a subset of patients with neuropathic Long COVID.8

However, antibody detection is not equivalent to proof of pathogenicity.

An antibody may represent an epiphenomenon, a marker of immune activation, or a clinically irrelevant finding. The pathogenic significance of specific autoantibodies in Long COVID-associated neuropathy therefore requires replication, functional studies, and treatment-response data.

Endothelial and Neurovascular Dysfunction

Peripheral nerves depend on an extensive microvascular supply. The endoneurial circulation provides oxygen and metabolic substrates to axons and Schwann cells.

Endothelial dysfunction, abnormal vascular tone, microvascular inflammation, and impaired oxygen utilization have all been proposed as components of Long COVID.10

The association between SFN and dysautonomia raises the possibility that peripheral nerve dysfunction and vascular dysregulation may represent interconnected manifestations of a broader neurovascular disorder.

Persistent Viral Antigen

Persistent SARS-CoV-2 RNA or protein has been identified in several tissues after acute infection. Whether these findings represent persistent replication, residual antigen, or cellular debris remains uncertain.

Persistent antigen could theoretically maintain immune activation and contribute to chronic inflammation or autoimmunity.

At present, however, there is insufficient evidence to conclude that persistent viral replication is the principal cause of Long COVID neuropathy.

Complement and Thromboinflammation

Complement activation and coagulation abnormalities are prominent features of acute COVID-19 and remain mechanistically interesting in Long COVID.

Microvascular injury could theoretically impair endoneurial perfusion and contribute to axonal dysfunction.

The hypothesis remains plausible but incompletely demonstrated in human peripheral nerve tissue.

Neuroimmune Signaling

Peripheral nociceptors are active participants in immune signaling. Cytokines and inflammatory mediators can alter neuronal excitability without producing immediately visible structural degeneration.

This distinction may be important because symptoms can sometimes improve before measurable nerve-fiber density normalizes.

A purely structural model of SFN may therefore be insufficient.

Genomics and Host Susceptibility

The genetic architecture of Long COVID remains incompletely defined.

Genome-wide association studies have identified candidate loci associated with susceptibility to Long COVID, while other studies have investigated HLA variation, immune-response genes, and host factors affecting the response to SARS-CoV-2.11-13

Whether these genetic associations specifically predict peripheral neuropathy is unknown.

Several biological pathways merit investigation:

antigen presentation;
innate viral recognition;
interferon signaling;
B-cell activation;
T-cell regulation;
complement;
endothelial function;
neuronal excitability;
axonal transport; and
nerve regeneration.

At present, genetic testing has no established role in diagnosing Long COVID neuropathy.

A future precision-medicine approach might identify genetically predisposed subgroups, but such a model requires large, ethnically diverse, prospectively phenotyped cohorts.

Pathology

The most clinically useful pathological marker of SFN is intraepidermal nerve-fiber density.

Small fibers extend from the dermis into the epidermis, where they can be visualized immunohistochemically. A reduction in fiber density below validated normative thresholds supports a diagnosis of SFN.

Skin biopsy has several advantages:

it is minimally invasive;
it provides objective structural evidence;
it can identify length-dependent and non–length-dependent patterns; and
it can be repeated in research settings.

Its limitations are equally important. SFN can be patchy; normative values vary with age and other factors; and functional abnormalities may occur without substantial structural fiber loss.

Consequently, a normal biopsy does not absolutely exclude SFN.

Conversely, reduced fiber density should not automatically be attributed to COVID-19 because SFN has numerous causes, including diabetes, impaired glucose tolerance, alcohol exposure, autoimmune disease, chemotherapy, vitamin deficiency, monoclonal gammopathy, amyloidosis, and hereditary disorders.

Clinical History and Physical Examination

The temporal relationship between SARS-CoV-2 infection and neurological symptoms should be documented precisely.

Important questions include:

When was the SARS-CoV-2 infection?
Was infection laboratory confirmed?
How severe was the acute illness?
Was hospitalization required?
Was intensive care required?
When did neurological symptoms begin?
Did symptoms begin during infection or after recovery?
Has the patient experienced reinfection?
Are symptoms continuous or episodic?
Are they worsened by exertion?
Are autonomic symptoms present?
Was neuropathy present before COVID-19?

The neurological examination should assess:

cranial nerves;
muscle bulk;
tone;
strength;
reflexes;
pinprick;
temperature;
vibration;
proprioception;
gait;
tandem gait;
Romberg sign;
coordination; and
autonomic signs.

Orthostatic heart rate and blood pressure should be measured when symptoms suggest dysautonomia.

Differential Diagnosis

A diagnosis of Long COVID should never terminate the diagnostic process.

Common causes of neuropathy remain common after COVID-19.

Metabolic and Nutritional Causes

Diabetes and impaired glucose tolerance are major causes of SFN. Hemoglobin A1c and glucose testing should therefore be routine components of the evaluation.

Vitamin B12 deficiency may produce sensory neuropathy and proprioceptive dysfunction. Serum B12 with methylmalonic acid testing when indicated is appropriate.

Thyroid dysfunction, copper deficiency, vitamin B6 toxicity, and other metabolic abnormalities should be considered according to clinical circumstances.

Monoclonal Gammopathy and Amyloidosis

Serum protein electrophoresis and immunofixation are important in otherwise unexplained neuropathy.

Amyloidosis should be considered when neuropathy is accompanied by autonomic dysfunction, cardiomyopathy, proteinuria, unexplained weight loss, or other systemic features.

Autoimmune Disease

Sjögren syndrome, vasculitic neuropathy, sarcoidosis, connective-tissue disease, and celiac disease can produce SFN.

The evaluation should be phenotype directed rather than indiscriminately testing large numbers of autoantibodies.

Toxic and Drug-Induced Neuropathy

Alcohol, chemotherapy, certain antimicrobials, vitamin B6 excess, and other medications can cause peripheral neuropathy.

A complete medication and supplement history is therefore essential.

Renal Disease

Advanced kidney disease can cause uremic neuropathy and can also alter the pharmacokinetics of drugs used to treat neuropathic pain.

Structural Neurological Disease

Spinal stenosis, radiculopathy, myelopathy, plexopathy, and entrapment neuropathies must remain in the differential diagnosis, particularly when symptoms are asymmetric, dermatomal, or associated with objective weakness.

Laboratory and Diagnostic Testing

No laboratory test currently confirms Long COVID neuropathy.

Testing should instead accomplish 3 goals:

identify common treatable causes;
establish the neurological phenotype; and
determine whether additional testing is necessary.

A practical initial laboratory evaluation includes:

complete blood count;
comprehensive metabolic panel;
fasting glucose and hemoglobin A1c;
vitamin B12;
methylmalonic acid when appropriate;
thyroid-stimulating hormone;
serum protein electrophoresis;
serum immunofixation; and
phenotype-directed inflammatory or autoimmune testing.

Additional tests should be guided by history and examination.

Electrodiagnostic Studies

Nerve-conduction studies and electromyography are indispensable when large-fiber neuropathy, weakness, radiculopathy, motor neuropathy, or demyelinating disease is suspected.

Their major limitation is their relative insensitivity to SFN.

Thus:

Normal NCS/EMG + persistent neuropathic symptoms ≠ absence of neuropathy.

When the clinical phenotype strongly suggests SFN, further evaluation should be considered.

Skin Biopsy

Skin biopsy is currently one of the most useful objective tests for suspected SFN.

The distal leg is a common sampling site, sometimes supplemented by a proximal specimen.

Reduced intraepidermal nerve-fiber density supports the diagnosis when interpreted against validated normative standards.

In selected post-COVID cohorts, substantial proportions of symptomatic patients have demonstrated reduced fiber density.5-8

These studies are important but have substantial referral and selection limitations.

The prevalence of biopsy-confirmed SFN among all patients with Long COVID therefore remains unknown.

Quantitative Sensory Testing

QST measures sensory thresholds for thermal and mechanical stimuli.

It can demonstrate abnormalities compatible with small-fiber dysfunction and may complement biopsy findings.

Because QST requires active patient participation, it is susceptible to cognitive, psychological, attentional, and reporting effects.

It should therefore be interpreted in conjunction with the clinical examination and, when appropriate, structural testing.

Autonomic Testing

Autonomic evaluation is appropriate when symptoms suggest dysautonomia.

Testing may include:

active stand testing;
tilt-table testing;
heart-rate variability;
Valsalva testing;
quantitative sudomotor axon reflex testing;
thermoregulatory sweat testing.

Autonomic abnormalities should be characterized rather than simply labeled “dysautonomia.”

Postural tachycardia, orthostatic hypotension, neurogenic orthostatic hypotension, sudomotor dysfunction, and gastrointestinal autonomic dysfunction have different clinical implications.

Treatment

Treatment should be individualized according to phenotype and cause.

Correct Identifiable Causes

Diabetes, vitamin deficiency, thyroid disease, monoclonal gammopathy, nutritional abnormalities, toxic exposures, and autoimmune disease should be treated according to established standards.

A causal attribution to Long COVID should not delay treatment of another identifiable disorder.

Neuropathic Pain

Conventional neuropathic pain therapies include:

duloxetine;
venlafaxine;
gabapentin;
pregabalin;
selected tricyclic antidepressants;
topical lidocaine; and
topical capsaicin.

Choice should reflect age, renal function, hepatic function, cardiovascular status, cognition, fall risk, and concurrent medications.

No medication in this group has been proven specifically to reverse Long COVID-associated nerve injury.

Autonomic Dysfunction

Management should be phenotype specific.

Depending on the patient, approaches may include:

adequate fluid and salt intake when medically appropriate;
compression garments;
gradual positional transitions;
avoidance of excessive heat;
recumbent activity when tolerated;
pharmacological treatment of orthostatic hypotension or tachycardia when indicated.

These interventions should be individualized, particularly in patients with hypertension, heart failure, kidney disease, or other conditions in which aggressive fluid or sodium loading may be inappropriate.

Rehabilitation

Rehabilitation should focus on function rather than simply increasing exercise volume.

Patients with postexertional malaise require careful pacing and energy management. Rehabilitation that repeatedly provokes substantial postexertional deterioration may be counterproductive.

Balance training, assistive devices, occupational adaptation, fall prevention, and sensory compensation can be more important than conventional aerobic conditioning in patients with substantial sensory loss.

Immunotherapy

Immunotherapy represents the most consequential unresolved therapeutic question.

Small observational studies have reported symptomatic improvement after IVIG in patients with Long COVID-associated SFN.6-8 These observations are biologically interesting because they are compatible with an immune-mediated mechanism.

They are not, however, sufficient to establish efficacy.

Uncontrolled studies cannot reliably distinguish treatment response from natural history, regression to the mean, placebo effects, selection bias, or concurrent interventions.

Furthermore, IVIG carries substantial cost and potential adverse effects, including headache, thrombosis, renal complications, hemolysis, and aseptic meningitis.

Accordingly, IVIG should presently be considered investigational for Long COVID-associated SFN.

A rational trial would require:

objective evidence of SFN;
standardized biopsy methodology;
standardized autonomic testing;
predefined neurological outcomes;
patient-reported outcomes;
adequate follow-up;
blinded placebo control; and
stratification according to immune phenotype.

The central question should not simply be whether IVIG improves symptoms.

It should determine whether IVIG changes the biological trajectory of the disease.

Prognosis and Recovery

The natural history of Long COVID-associated neuropathy remains poorly defined.

Available observational studies indicate that some patients improve substantially over several months, whereas others experience persistent or relapsing symptoms.5-8

Three different outcomes should be distinguished:

Symptomatic recovery: reduction in pain, paresthesias, or autonomic symptoms.

Functional recovery: restoration of walking, balance, occupational ability, and activities of daily living.

Biological recovery: restoration of nerve-fiber density or normalization of physiological measures.

These outcomes may occur at different rates.

A patient may experience substantial pain relief while retaining objective sensory abnormalities. Conversely, nerve-fiber regeneration may occur while pain persists because of altered peripheral or central nociceptive processing.

Long-term prognosis is therefore unlikely to be adequately described by a single symptom score.

Predictors of Outcome

Reliable predictors of recovery have not been established.

Potentially important variables include:

severity of initial infection;
age;
metabolic disease;
diabetes;
renal disease;
preexisting neuropathy;
severity of autonomic dysfunction;
postexertional malaise;
extent of objective nerve-fiber loss;
duration of symptoms before diagnosis; and
presence of multisystem Long COVID.

These variables should be regarded as hypotheses rather than validated prognostic factors.

Conclusions

Long COVID-associated peripheral neuropathy represents a clinically important but biologically heterogeneous neurological syndrome.

The strongest current evidence concerns small-fiber neuropathy, in which selected patients with persistent post-COVID neuropathic symptoms demonstrate reduced intraepidermal nerve-fiber density despite normal conventional nerve-conduction studies.

The existence of objective small-fiber pathology changes the clinical conversation.

Patients with persistent neuropathic symptoms should not be dismissed solely because routine electrodiagnostic studies are normal. At the same time, reduced nerve-fiber density should not automatically be attributed to SARS-CoV-2. Diabetes, nutritional deficiency, monoclonal gammopathy, autoimmune disease, toxic exposures, renal disease, amyloidosis, hereditary neuropathy, and structural neurological disease remain important alternative diagnoses.

The pathogenesis of Long COVID neuropathy is probably heterogeneous. Immune dysregulation, autoimmunity, endothelial dysfunction, neurovascular abnormalities, persistent antigen, complement activation, and altered neuroimmune signaling represent plausible mechanisms, but none has been demonstrated to account for the majority of cases.

Genomics may eventually permit biological stratification, but no validated genetic test presently exists.

Diagnosis should therefore be phenotype driven. History and neurological examination establish the clinical syndrome; laboratory testing excludes common causes; NCS/EMG evaluates large-fiber disease; skin biopsy and QST investigate SFN; and autonomic testing characterizes dysautonomia.

Treatment should currently emphasize correction of identifiable causes, neuropathic pain control, autonomic management, rehabilitation, fall prevention, and preservation of function.

Immunotherapy is the principal unresolved therapeutic question. Preliminary observations concerning IVIG are sufficiently compelling to justify randomized trials but insufficient to justify its routine use as established treatment for Long COVID-associated SFN.

The next stage of the field should move beyond the broad label of Long COVID toward biologically defined neurological phenotypes.

A patient with biopsy-confirmed SFN, autonomic dysfunction, postexertional malaise, and evidence of immune activation may represent a fundamentally different biological entity from a patient with isolated distal paresthesias caused by diabetes who happened to have COVID-19.

The distinction is not semantic.

It determines prognosis, treatment, trial eligibility, and ultimately whether a disease-modifying therapy can be identified.

Long COVID neuropathy should therefore be approached neither with diagnostic skepticism nor with uncritical attribution. The appropriate position is more demanding: demonstrate the neurological phenotype, exclude competing causes, investigate the biological mechanism, treat what can presently be treated, and subject proposed disease-modifying therapies to the same evidentiary standards applied to other neurological diseases.

References

World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. World Health Organization; 2021.
World Health Organization. Coronavirus disease (COVID-19): post COVID-19 condition. Updated March 28, 2023.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z.
Abrams RMC, Simpson DM, Navis A, et al. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve. 2022;65(4):440-443. doi:10.1002/mus.27458.
McAlpine LS, Zubair AS, Farhat N, et al. Small-fiber neuropathy associated with SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2024;11(3). doi:10.1212/NXI.0000000000200244.
Drobinska N, Nehme M, Assal F, et al. Small fiber neuropathy in long COVID: a cohort study with multimodal assessment and follow-up. Eur Neurol. 2025;88(2):52-63. doi:10.1159/000546015.
Maguire C, et al. Analysis of 977 Long COVID Patients Reveals Prevalent Neuropathy and Association with Anti-Ganglioside Antibodies. medRxiv. Published 2025. Preprint. This study should be identified as a preprint unless and until a peer-reviewed publication supersedes it.
Yin K, Peluso MJ, Luo X, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024;25:218-225. doi:10.1038/s41590-023-01724-6.
Sui J, Noubouossie D, Wiersinga WJ, et al. Long COVID and the vascular system: endothelial dysfunction, microvascular abnormalities, and implications for persistent disease. [Use the final peer-reviewed source selected during manuscript verification.]
Xie J, Mothe B, Alcalde Herraiz M, et al. Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes. Nat Commun. 2024;15. [Final article details should be verified against the publisher record before submission.]
Torki E, Hoseininasab F, Moradi M, et al. The demographic, laboratory and genetic factors associated with long COVID-19 syndrome: a case-control study. Inflamm Res. 2024;73. doi:10.1007/s00011-023-01697-2.
The COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472-477. doi:10.1038/s41586-021-03767-x.
Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature. 2024. doi:10.1038/s41586-024-07873-4.
Appelman B, Charlton BT, Goulding RP, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024;15. doi:10.1038/s41467-023-44432-3.
Greene C, Connolly R, Brennan D, et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024.
England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing. Neurology. 2009;72(2):185-192. doi:10.1212/01.wnl.0000336370.51010.a1. Reaffirmed by the American Academy of Neurology in 2025.
Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol. 2010;17(7):903-912. doi:10.1111/j.1468-1331.2010.03023.x.
Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(pt 7):1912-1925. doi:10.1093/brain/awn093.
Devigili G, Rinaldo S, Lombardi R, et al. Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain. 2019;142(12):3721-3736. doi:10.1093/brain/awz333.
Hoeijmakers JGJ, Faber CG, Lauria G, Merkies ISJ, Waxman SG. Small-fibre neuropathies—advances in diagnostic evaluation. Nat Rev Neurol. 2012;8(7):369-379. doi:10.1038/nrneurol.2012.97.
Oaklander AL, Klein MM. Evidence of somatosensory small-fiber polyneuropathy in unexplained, widespread chronic pain. Pain. 2013;154(11):2310-2316. doi:10.1016/j.pain.2013.06.031.
Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-2293. doi:10.2337/dc10-1303.
Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA. 2015;314(20):2172-2181. doi:10.1001/jama.2015.13611.
Callaghan BC, Gallagher G, Fridman V, Feldman EL. Diabetic neuropathy: what does the future hold? Diabetologia. 2020;63(5):891-897. doi:10.1007/s00125-020-05185-4.
Ziegler D, Tesfaye S, Spallone V, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice. Diabetes Res Clin Pract. 2018;139:196-209. doi:10.1016/j.diabres.2018.03.039.
Freeman R. Autonomic peripheral neuropathy. Lancet. 2005;365(9466):1259-1270. doi:10.1016/S0140-6736(05)74815-6.
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. doi:10.1007/s10286-011-0119-5.
Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome. Can J Cardiol. 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1.
van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023;30(12):3646-3674.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2021;26(3):242-268.
Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9). doi:10.1002/14651858.CD002063.pub6.
Dalakas MC. Update on the diagnosis and management of CIDP. Nat Rev Neurol. 2011;7(9):507-517. doi:10.1038/nrneurol.2011.121.
Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations in patients with long COVID. [Reference should be replaced by the final peer-reviewed source selected after database verification.]
McAlpine LS, et al. Case-control investigation of small-fiber neuropathy and dysautonomia following COVID-19. Neurol Neuroimmunol Neuroinflamm. 2024.
Falco P, et al. Autonomic small fiber involvement in painful long COVID: a histological and clinical study. Front Hum Neurosci. 2026.
Khoo A, Manuel K, Ng T, Crotty M. Non-invasive electrodiagnostic testing for small fibre neuropathy in long COVID-19. BMJ Neurol Open. 2026;8(1). doi:10.1136/bmjno-2025-001399.
Gibbons CH, Rajan S, Senechal K, et al. A double-blind placebo-controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS-HDS and FGFR-3 autoantibodies. Muscle Nerve. 2023. doi:10.1002/mus.27745.
Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-fiber polyneuropathy. JAMA Neurol. 2019;76(11):1240-1251. doi:10.1001/jamaneurol.2019.2917.
Hovaguimian A, Gibbons CH. Clinical approach to the treatment of painful diabetic neuropathy. Ther Adv Endocrinol Metab. 2011;2(1):27-38. doi:10.1177/2042018810391041.
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0.
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(7).
Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2014;(4).
Moore RA, Wiffen PJ, Derry S, Rice ASC. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2019;(1).
Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2014;(1).
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-819. doi:10.1016/S1474-4422(10)70143-5.
Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. doi:10.1038/nrdp.2017.2.
Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153-1169.
Tesfaye S, Boulton AJM, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36(9):2456-2465. doi:10.2337/dc12-1964.
Oaklander AL, Rissmiller JG, Gelman LB, Zheng L, Chang Y, Gott R. Evidence of small-fiber polyneuropathy in unexplained chronic pain. Pain. 2013;154(11):2310-2316.
Gibbons CH, Freeman R. Autonomic neuropathy and small fiber neuropathy. Continuum (Minneap Minn). 2015;21(5):1165-1182.
Freeman R, Chapleau MW. Testing the autonomic nervous system. Handb Clin Neurol. 2013;115:115-136.
Illigens BMW, Gibbons CH. Sweat testing. Auton Neurosci. 2009;150(1-2):1-7.
Low PA. Composite autonomic scoring scale. Auton Neurosci. 1999;77(2-3):101-105.
Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies guidelines on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol. 2010;17(7):903-912.
Ebenezer GJ, Hauer P, Gibbons C, McArthur JC, Polydefkis M. Assessment of epidermal nerve fibers: a new diagnostic technique for peripheral neuropathies. Brain. 2007;130(pt 6):1461-1467.
McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol. 1998;55(12):1513-1520.
Lauria G, Lombardi R. Skin biopsy: a new tool for diagnosing peripheral nerve disease. BMJ. 2007;334(7606):1159-1162.
Devigili G, Cazzato D, Lauria G. Clinical diagnosis and management of small fiber neuropathy. Curr Opin Neurol. 2020;33(5):614-622.
Oaklander AL. Immunotherapy for small fiber neuropathy: current evidence and future directions. [Final source should be verified before submission.]
Gibbons CH, Rajan S, Senechal K, et al. A double-blind placebo-controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS-HDS and FGFR-3 autoantibodies. Muscle Nerve. 2023.
Lewis RA, et al. Immunoglobulin therapy in autoimmune neuropathy: principles of patient selection and outcome assessment. [Verify final bibliographic record before submission.]
Dalakas MC. Intravenous immunoglobulin in autoimmune neurological disorders. JAMA Neurol. 2020;77(8):1010-1018.
Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long COVID. Lancet Infect Dis. 2022;22(9).
Peluso MJ, Deeks SG. Mechanisms of long COVID. N Engl J Med. 2023;389:1375-1386.
Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019.
Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13:1957.
Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-461.
Taquet M, Dercon Q, Harrison PJ. Six-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19. Lancet Psychiatry. 2021;8(5):416-427.
Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies. Lancet Psychiatry. 2022;9(10):815-827.
Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697-707.
Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623:139-148.
Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20.
Pretorius E, Venter C, Laubscher GJ, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19. Cardiovasc Diabetol. 2021;20:172.
Turner S, et al. Long COVID and endothelial dysfunction: current evidence and mechanisms. [Verify final source.]
Lee J, et al. Persistent immune dysregulation in post-acute COVID-19 syndrome. [Verify final source.]
Klein J, et al. Immune signatures of long COVID. Nature. 2023.
Yin K, Peluso MJ, Luo X, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024;25:218-225.
Peluso MJ, Deeks SG. Long COVID: mechanisms and management. [Verify final publication details before submission.]
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19: defining the pathogenesis and disease spectrum. Front Microbiol. 2021;12:690169.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019. JAMA. 2020;324(8):782-793.
Nalbandian A, et al. Long COVID: clinical features and pathophysiological mechanisms. [Verify final publication details.]
Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370.
Centers for Disease Control and Prevention. Long COVID Clinical Guidance. Updated 2026.
National Academies of Sciences, Engineering, and Medicine. A Long COVID Definition: A Chronic, Systemic Disease State With Profound Consequences. National Academies Press; 2024.
Writing Committee for the RECOVER Initiative. RECOVER-Adult Long COVID Research Index. JAMA. 2025;333(8):694-700.
Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and clinical correlates of long COVID in the United States. [Verify final source.]
Global Burden of Disease Long COVID Collaborators. Global burden of 19 health conditions associated with long COVID. [Verify final bibliographic record.]
Bowe B, Xie Y, Al-Aly Z. Global incidence and mortality of long COVID. [Verify final source.]
Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461-1467.
Xie Y, Choi T, Al-Aly Z. Long-term outcomes following COVID-19 vaccination: implications for post-acute sequelae. [Verify final source.]
Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(1):43-55.
Krumholz HM, et al. Long COVID: a call for interdisciplinary research. [Verify final source.]
Davis HE, McCorkell L, Moore K, et al. Patient-led research and long COVID. [Verify final source.]
World Health Organization. Post COVID-19 condition: clinical and research priorities. World Health Organization.
National Institutes of Health. Researching COVID to Enhance Recovery (RECOVER): Long COVID research initiative.
American Academy of Neurology. Evaluation of distal symmetric polyneuropathy: laboratory and genetic testing guideline. Reaffirmed February 8, 2025.